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SALSA: A Regulator of the early 
Steps of Complement Activation on 
Mucosal Surfaces
Martin Parnov Reichhardt and Seppo Meri*
Immunobiology Research Program, Research Programs Unit, Department of Bacteriology and Immunology, Haartman 
Institute, University of Helsinki, Helsinki, Finland
Complement is present mainly in blood. However, following mechanical damage or 
inflammation, serous exudates enter the mucosal surfaces. Here, the complement 
proteins interact with other endogenous molecules to keep microbes from entering 
the parenteral tissues. One of the mucosal proteins known to interact with the early 
complement components of both the classical and the lectin pathway is the salivary 
scavenger and agglutinin (SALSA). SALSA is also known as deleted in malignant brain 
tumors 1 and gp340. It is found both attached to the epithelium and secreted into the 
surrounding fluids of most mucosal surfaces. SALSA has been shown to bind directly to 
C1q, mannose-binding lectin, and the ficolins. Through these interactions SALSA regu-
lates activation of the complement system. In addition, SALSA interacts with surfactant 
proteins A and D, secretory IgA, and lactoferrin. Ulcerative colitis and Crohn’s disease are 
examples of diseases, where complement activation in mucosal tissues may occur. This 
review describes the latest advances in our understanding of how the early complement 
components interact with the SALSA molecule. Furthermore, we discuss how these 
interactions may affect disease propagation on mucosal surfaces in immunological and 
inflammatory diseases.
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inTRODUCTiOn
Activation of the complement system is strongly involved in generating inflammation, combatting 
microbial infections, and participating in clearance of non-viable tissue. Although complement is 
present mainly in blood, it is also found in serous exudates on mucosal surfaces, such as in the oral 
cavity or the airways (1, 2). This is particularly seen after mechanical, infectious, or immune damage, 
e.g., in periodontal disease or SLE (3). When serous exudates enter the mucosal surfaces, innate 
immune proteins interact with mucosal surface proteins. Together, these molecules participate in 
clearance and defense against invading microorganisms. Although bleeding at the mucosal surfaces 
is observed daily, even in healthy individuals, the role of the complement system in this environment 
has so far been studied very little. Of particular interest would be the need to suppress complement-
mediated inflammation, while still mediating the antimicrobial defense functions.
TABLe 1 | endogenous and microbial ligands of SALSA.
endogenous 
ligand
Suggested functional relevance
C1q Complement regulation (4)
MBL Complement regulation (6)
Ficolins Complement regulation (6)
SpD Microbial agglutination (9)
SpA Microbial agglutination (16)
IgA Microbial agglutination (8)
Lactoferrin Bacterial binding (20)
DNA Inflammation (21)
Heparan sulfate Inflammation (21)
Trefoil factors Tissue homeostasis (17)
MUC5B Microbial agglutination (22)
Fibrin Not known (19)
Fibrinogen Not known (19)
Erythrocytes Aggregation (19)
Platelets Aggregation (19)
Microbe Specific strains
Streptococcus S. pyogenes, S. agalactiae, S. pneumonia, S. mutans, S. mitis, 
S. oralis, S. salivarius, S. gordonii, S. crista, S. parasanguinis, 
S. vestibularis, S. intermedius, S. anginosus, S. suis (7, 23–25)
Lactobacillus L. rhamnosus, L. casei, L. reuteri, L. lactis (26)
Other bacteria Staphylococcus aureus, Bifidobacterium, Actinomyces, 
Salmonella enterica serovar Typhimurium, Helicobacter pylori, 
Haemophilus influenzae, Klebsiella oxytoca (23–28)
Viruses HIV, IAV (29, 30)
The listed ligands have been found to bind either human SALSA, the murine-ortholog 
of SALSA, or the recombinantly expressed bacterial-binding peptide, SRCRP2.
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Salivary Scavenger and Agglutinin
One of the molecules at the mucosal surfaces that interact with the 
early complement components is a protein that we named salivary 
scavenger and agglutinin (SALSA) (4–7). SALSA, also known as 
gp340, “deleted in malignant brain tumors 1” (DMBT1), and sali-
vary agglutinin (SAG), was first described as a 300–400 kDa strep-
tococcus agglutinating agent from saliva (8–10). Subsequently, 
SALSA has been suggested to function in epithelial homeostasis, 
innate immunity, inflammation, and tumor suppression (11–13). 
Many of these functions are mediated through interactions with 
endogenous ligands. SALSA has been shown to bind the comple-
ment components C1q, mannose-binding lectin (MBL), and the 
ficolins (4, 6). Furthermore, SALSA has been found to interact 
with surfactant proteins A and D (SpA and SpD, respectively), 
secretory IgA, lactoferrin, fibrin/fibrinogen, trefoil factors, and 
mucin-5B (Table  1) (9, 14–19). The multiple binding partners 
suggest that SALSA plays a central role in regulating inflamma-
tion and immune responses on mucosal surfaces.
SALSA in Antimicrobial Defense
Salivary scavenger and agglutinin is expressed at most mucosal 
surfaces, including the lungs, oral cavity, gastrointestinal tract, 
and vagina (31–35). It has been found both attached to the epi-
thelium and secreted into the lining fluids, such as saliva, tear 
fluid, and respiratory mucosal secretions (8, 9, 14, 36). Recent 
studies detected SALSA in the amniotic fluid and in the intestines 
of neonates (37). SALSA was estimated to constitute up to 10% of 
the total protein amount in meconium and in the saliva of young 
children (<3 years), making it one of the most abundant proteins 
in these environments (37, 38).
On the mucosal surfaces, SALSA has been shown to regulate 
the local immune system. On one hand, it scavenges invading 
microorganisms, whereas, on the other hand, it interacts with the 
mucosal epithelium to improve the integrity of this physical bar-
rier (Figure 1A) (13, 39). SALSA binds a broad range of microbes, 
including viruses and bacteria (Table 1). Studies have shown that 
SALSA in the oral and intestinal mucosal secretions is sufficient 
to suppress infection by agglutinating microorganisms and keep-
ing them from infecting the tissue. This has been observed for 
Salmonella enterica, HIV-1, and influenza A-virus (IAV) (27, 29, 
30, 40). These studies suggested that SALSA simply functioned by 
agglutinating the microbes. However, the role of SALSA appears 
to be more complex than that. SALSA binds, e.g., to epithelial and 
tooth surfaces in addition to being secreted into the fluid phase 
(23). The epithelium-attached localization of a protein with a solely 
bacteria-agglutinating function would not appear to be beneficial 
for the human host. This paradox has been made clear by studies 
showing that SALSA, in some cases, may actually be exploited 
by the invading microbes. A study of dental caries showed that 
certain variants of the SALSA protein correlated positively with 
Streptococcus mutans adhesion to SALSA-coated hydroxyapatite 
surfaces and the development of dental caries. Other SALSA 
variants displayed the opposite correlation (41). In the case of 
HIV-1 infection, the salivary fluid SALSA protein was found to 
interfere with oral transmission. However, SALSA expressed on 
the vaginal epithelium had an enhancing effect on the infectivity 
of the virus (35). These findings suggest that some microbes have 
evolved mechanisms to utilize SALSA to infect the human body.
isoforms of the SALSA Protein
As indicated above, various variants of SALSA may interact differ-
ently with microbes. Indeed, different SALSA isoforms have been 
identified on various mucosal surfaces. These have been shown to 
vary both in protein sequence and in the glycosylation patterns 
(23, 36, 37). The gene for SALSA (in chromosome 10q26.13) 
encodes 13 highly conserved scavenger receptor cysteine-rich 
(SRCR) domains. These 109-amino acid-long motifs are found 
as “pearls on a string” separated by SRCR interspersed domains 
(SIDs) (Figure 1B). The stretch of 13 SRCR domains is followed 
by 2 C1r/C1s, urchin embryonic growth factor and bone morpho-
genetic protein-1 (CUB) domains encompassing the 14th SRCR 
domain. Finally, a zona pellucida (ZP) domain is found at the 
most C-terminal end (31, 42). The repetitive sequence of SRCR 
domains may facilitate alternative splicing (43). Indeed, mRNA 
transcripts encoding between 8 and 13 of the N-terminal SRCR 
domains have been observed, all in all revealing up to 7 distinct 
alleles (31, 42, 44). It has been estimated that SALSA contains 
25–45% (w/w) of carbohydrate (8, 31). SALSA contains all the 
major sugar components. However, differences have been found 
to correlate to the secretor [Se(+/−)] status (±expression of the 
α1-2fucosyl-transferase). The blood group antigens, ABO, and 
Lewis antigens b and y (Leb and Ley) were found on SALSA from 
Se(+) individuals. In contrast, SALSA from Se(−) individuals did 
not contain ABO, Leb nor Ley antigens. Instead, Lewis antigens a 
SRCR domain
CUB domain ZP domain
SRCR interspersed domain
A
B
IgA and IgGC1q/MBL/ficolins
SALSA
Epithelial damageHealthy epithelium
SpA/SpD
Lumen
Tissue
Microbe
I II III IV
Epithelial cell
FiGURe 1 | Function and structure of SALSA at the mucosal surfaces. (A) At the mucosal surfaces, the SALSA protein is mainly found associated with the 
epithelium and secreted into the surrounding fluids. The known features and functions of SALSA are presented in four panels (I–IV). (I) SALSA is present on the 
epithelial cell surface and deposited in the extracellular matrix, where it is involved in maintaining epithelial homeostasis. (II) Fluid-phase SALSA binds a broad array 
of microbes. It has been shown to agglutinate viruses, as well as both Gram-positive and Gram-negative bacteria thus preventing them from invading the parenteral 
spaces. (III) SALSA interacts with other endogenous molecules present at the mucosal surfaces, such as surfactant proteins SpA and SpD as well as IgA. It is 
believed that these molecules cooperate in antimicrobial defense. (IV) In the case of epithelial damage, cells and molecules from the tissue become mixed with the 
luminal contents. In this context, SALSA may bind the complement sensor molecules C1q, MBL, and the ficolins, thereby SALSA could initiate complement 
activation against distinct microbes or participate in the clearance of injured tissue components. (B) In its molecular structure, SALSA contains a stretch of 13 
scavenger receptor cysteine-rich (SRCR) domains separated by SRCR interspersed domains. These are followed by two C1r/C1s, urchin embryonic growth factor 
and bone morphogenetic protein-1 (CUB) domains surrounding the 14th SRCR domain. Finally, a zona pellucida (ZP) domain is found at the most C-terminal end of 
the protein.
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and x (Lea and Lex) were present (45, 46). Thus, different forms 
of the SALSA protein exist. They are produced both by variations 
in the protein chain and in the extent and nature of glycosyla-
tion. The SALSA protein composition varies not only between 
individuals but also in different body compartments within the 
same individual (23, 36, 37).
SALSA AnD COMPLeMenT
interactions of C1q, MBL, and Ficolins 
with SALSA
C1q, MBL, and ficolins all form bouquet-like structures, where 
each subunit contains a collagen-like domain (stalk) and a carboxy-
terminal globular domain (the “flower”) (47, 48). C1q binds specifi-
cally to surface-attached IgG and IgM. However, other endogenous 
non-immunoglobulin ligands have been found, including SALSA 
(4, 6). Also, MBL, M-ficolin, H-ficolin, and L-ficolin were found 
to bind to SALSA (6). All interactions between SALSA and the 
complement molecules were calcium dependent.
C1q was shown to bind SALSA through the globular domain in 
a region close to the immunoglobulin-binding site (49). Similarly, 
it appears that MBL utilizes the globular carbohydrate recognition 
domain (CRD) for the interaction with SALSA. Due to the heavy 
glycosylation of SALSA, sugar structures may function as a target 
for the CRD of MBL (8, 31). When the binding of MBL was tested 
to SALSA purified from the saliva of a single donor up to 60% 
inhibition of the SALSA–MBL interaction was observed when 
5  mM fucose was added to the fluid phase (7). MBL binds to 
the Leb antigen, a fucose-containing oligosaccharide (7). A clear 
difference was observed in the binding of MBL to SALSA from 
secretors vs. non-secretors (7). This correlates to the finding that 
only SALSA from Se(+) individuals contains the Leb antigen (45, 
46). This strongly suggests that MBL binds via the CRD to the Leb 
antigen of SALSA.
Complement Activation and Regulation by 
SALSA
It has been shown that the binding of C1q to SALSA is sufficient to 
initiate activation of the classical complement activation pathway 
(4, 6). In addition, SALSA was shown to influence the activation 
of the lectin pathway through interactions with MBL and the fico-
lins (5, 6). The overall outcome of SALSA-mediated complement 
regulation varies with the specific location of SALSA (6). SALSA 
coated onto a microtiter plate surface activated complement as 
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measured by deposition of C4b and C3b after incubation with 
normal human serum (NHS). Using MBL-deficient serum, 
approximately 30% of the total complement activation was lost 
(6). The residual activation is likely mediated by C1q and possibly 
also by the ficolins (4, 6). In contrast to complement activation 
observed by surface-bound SALSA, SALSA in the fluid phase 
caused a dose-dependent inhibition of the lectin pathway (6). No 
such effect was observed on the classical pathway, which may be 
due to the almost 100 times higher concentrations of C1q vs. MBL. 
SALSA was able to interfere with the binding of the MBL–MASP2 
complex to surface-coated mannan. Candida albicans is a known 
target for MBL-mediated complement activation. When NHS was 
mixed with increasing concentrations of SALSA and incubated 
with C. albicans a dose-dependent inhibition of the deposition of 
both C4b and C3b was observed on the Candida surface (6). The 
dual effects of SALSA on the complement system appear con-
tradictory at first glance. On one hand, by binding to MBL and 
ficolins in the fluid phase, SALSA can prevent their binding to 
targets. On the other hand, when bound to a surface, SALSA can 
direct complement activation against appropriate targets, such as 
microbes. Overall, it appears that SALSA is a mucosal first line 
recognition molecule that can distinguish between targets to be 
cleared vs. structures to be tolerated.
Increased SALSA expression may alone and in concert with, 
e.g., C1q and MBL, lead to increased microbial clearance. In addi-
tion to the interactions with the complement proteins, SALSA 
can also mediate its anti-bacterial and inflammation regulating 
functions through interactions with IgA, SpA, and SpD (8, 9, 16). 
The functional outcome of these interactions is a cooperative 
effect on the microbial agglutination (Figure 1A) (50, 51). SALSA, 
SpA, and SpD have a dual effect against IAV: viral agglutination 
and inflammatory modulation (52). The binding of the SALSA 
ligand SpD to IAV has been shown to induce a strong respiratory 
burst response in neutrophils in vitro. This response was reduced 
by the addition of SALSA (51). It has been suggested that this 
allows a regulated response by the neutrophils, with an increased 
uptake of IAV but without an excessive and potentially harmful 
burst response (13). A similar feature is observed in the case of 
C-reactive protein and the other pentraxins. They target C1q to 
apoptotic and necrotic tissue, while simultaneously recruiting 
factor H to limit the complement activation (53, 54). This process 
is relevant during the removal of apoptotic debris at the mucosal 
surfaces, as well (55). The differential outcome of the interaction 
of SALSA with complement may represent a similar balanced 
effector mechanism against invading microbes.
SALSA AnD COMPLeMenT in 
inFLAMMATORY BOweL DiSeASe
Intestines are one of the primary sites, where an imbalance 
between activation and control of immune responses leads to 
disease. Inflammatory bowel disease (IBD) encompasses two 
chronic relapsing and remitting inflammatory conditions of the 
gastrointestinal tract. These are known as ulcerative colitis (UC) 
and Crohn’s disease (CD). Together, they affect up to 1:250 in 
the adult population (56). In children, the incidence of IBD is on 
the rise. Disease onset is during childhood or adolescence for up 
to 25% of the patients; although the mortality of the disease has 
been declining, it has a major impact on the development of these 
young individuals (57). The fundamental causes of the diseases 
are still obscure.
Several associations have been found between complement 
components and IBD. Specifically for the gut mucosa, the devel-
opment of CD has been associated with an altered expression of 
components of the lectin pathway. The frequency of the MBL2 gene 
allele, which results in MBL deficiency, was significantly elevated 
in pediatric patients with CD compared to healthy controls or 
adults with Sjögren’s syndrome (58, 59). Deficiencies in classical 
and alternative pathway components are rarer. Some patients 
deficient in C1 inhibitor, which is commonly associated with 
hereditary angioedema, were found to develop non-infectious 
enteritits and IBD (60–62). To further highlight an involvement 
of the classical and lectin pathways of complement, we recently 
observed an association of pediatric IBD to an MHC haplotype 
that involves a deficiency of two C4 genes (HLA-A03; HLA-B07; 
one C4A gene; one C4B gene; HLA-DRB115) (63).
A study of lectin pathway components during CD treatment 
found a dramatic impact on M-ficolin and MASP-3 levels in 
patients responding to anti-TNF-α therapy (64). However, how 
the complement components specifically affect the local inflam-
matory environment of the gut is not clear yet. The above described 
interactions with the SALSA molecule present a potential way 
for complement to affect a balanced mucosal immunological 
response. Current models of CD pathogenesis include an altered 
response to the local microbiota, and an increased SALSA expres-
sion has been linked to several of these responses (65). Studies 
have shown that SALSA can be strongly induced by various 
immunological stimuli (66, 67). The increased levels of SALSA in 
the intestinal epithelium of patients with IBD and in the ethmoid 
sinusoidal mucosa of patients with chronic sinusitis suggest that 
SALSA expression is part of the mucosal inflammatory response 
(66–68). Furthermore, a study of preterm infants revealed that an 
increase in the pulmonary SALSA levels was part of the mucosal 
response to neonatal infection (69).
Salivary scavenger and agglutinin expression by the intesti-
nal epithelium is induced by NOD2 and TLR4 activation (27). 
However, the outcome of an induced SALSA expression during 
IBD may not necessarily lead to enhanced clearance only. Rather, 
the interaction of SALSA with several endogenous molecules may 
be part of an efficient but limited immunological response. Failure 
in these processes could propagate an unbalanced and overactive 
local immune response in IBD. It has been shown that the previ-
ously described SALSA isoforms influence both the interaction 
with microbes and the endogenous ligands, such as IgA, C1q, 
and MBL (37). Interestingly, the specific bacterial-binding ability 
of SALSA has been found to depend not only on the isoform of 
the protein but also on the location of the protein. Fluid-phase 
SALSA can bind and aggregate some streptococcal strains, while 
SALSA coated to a hydroxyapatite surface does not (23). Thus, 
the association with the mucosal epithelium or the secretion 
into the lining fluids may further affect the local immunological 
environment differently. Finally, the described interaction of 
SALSA and trefoil factors, being important in maintaining the 
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mucosal epithelial barrier, has also been suggested to play a role 
in IBD (70, 71).
Salivary scavenger and agglutinin may be part of the normal 
immunological response of the mucosal epithelium during infec-
tion. Individual variations in the expression of SALSA isoforms 
alternate the ability of SALSA to interact with endogenous 
ligands, to invade microbes, and perhaps even to induce a limited 
burst response in neutrophils. It is therefore not surprising that a 
specific SALSA isoform, lacking the five most N-terminal SRCR 
domains, has been associated with CD (65, 67).
We speculate that the individual variations in the SALSA inter-
actions are key in understanding how this molecule could play 
a role in shifting the immunological balance toward increased 
inflammation at the mucosal surfaces, with detrimental effects 
for IBD patients.
FUTURe PeRSPeCTiveS
At the mucosal surfaces, a very tight immunological response 
to infection and inflammation is essential. The SALSA molecule 
is central player interacting with a multitude of endogenous 
molecules, invading microbes and the epithelial barrier. Due to 
the tightly linked interactions, a balanced function of the SALSA 
molecule is key in avoiding an overactive immune response. 
The interplay between the various SALSA isoforms, ficolins, 
MBL, and C1q with modified tissue components, carbohydrates, 
acetylated molecules, and microbes on mucosal surfaces provides 
an interesting area for future research that may open a new under-
standing of mechanisms underlying the development of mucosal 
immunological disorders.
AUTHOR COnTRiBUTiOnS
Both authors contributed to the design and writing of this 
review.
FUnDinG
This work was supported by the Helsinki Biomedical Graduate 
Program, the Jenni and Antti Wihuri foundation, Helsinki 
University Central Hospital funds (EVO), the Sigrid Jusélius 
Foundation, Signe and Ane Gyllenberg Foundation, Magnus 
Ehrnrooth Foundation, Helsinki University Funds, the 
Stockmann Foundation, and the Academy of Finland.
ReFeRenCeS
1. Boackle RJ. The interaction of salivary secretions with the human complement 
system – a model for the study of host defense systems on inflamed mucosal 
surfaces. Crit Rev Oral Biol Med (1991) 2:355–67. 
2. Persson CG, Erjefalt I, Alkner U, Baumgarten C, Greiff L, Gustafsson B, et al. 
Plasma exudation as a first line respiratory mucosal defence. Clin Exp Allergy 
(1991) 21:17–24. doi:10.1111/j.1365-2222.1991.tb00799.x 
3. Courts FJ, Boackle RJ, Fudenberg HH, Silverman MS. Detection of functional 
complement components in gingival crevicular fluid from humans with 
periodontal diseases. J Dent Res (1977) 56:327–31. doi:10.1177/0022034577
0560032001 
4. Boackle RJ, Connor MH, Vesely J. High molecular weight non-immunoglobu-
lin salivary agglutinins (NIA) bind C1Q globular heads and have the potential 
to activate the first complement component. Mol Immunol (1993) 30:309–19. 
doi:10.1016/0161-5890(93)90059-K 
5. Leito JT, Ligtenberg AJ, van Houdt M, van den Berg TK, Wouters D. The 
bacteria binding glycoprotein salivary agglutinin (SAG/gp340) activates com-
plement via the lectin pathway. Mol Immunol (2011) 49:185–90. doi:10.1016/j.
molimm.2011.08.010 
6. Reichhardt MP, Loimaranta V, Thiel S, Finne J, Meri S, Jarva H. The salivary 
scavenger and agglutinin binds MBL and regulates the lectin pathway of com-
plement in solution and on surfaces. Front Immunol (2012) 3:205. doi:10.3389/
fimmu.2012.00205 
7. Gunput ST, Ligtenberg AJ, Terlouw B, Brouwer M, Veerman EC, Wouters D. 
Complement activation by salivary agglutinin is secretor status dependent. 
Biol Chem (2015) 396:35–43. doi:10.1515/hsz-2014-0200 
8. Ericson T, Rundegren J. Characterization of a salivary agglutinin reacting with 
a serotype c strain of Streptococcus mutans. Eur J Biochem (1983) 133:255–61. 
doi:10.1111/j.1432-1033.1983.tb07456.x 
9. Holmskov U, Lawson P, Teisner B, Tornoe I, Willis AC, Morgan C, et  al. 
Isolation and characterization of a new member of the scavenger receptor 
superfamily, glycoprotein-340 (gp-340), as a lung surfactant protein-D bind-
ing molecule. J Biol Chem (1997) 272:13743–9. doi:10.1074/jbc.272.21.13743 
10. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus 
KK, et al. DMBT1, a new member of the SRCR superfamily, on chromosome 
10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet (1997) 17:32–9. 
doi:10.1038/ng0997-32 
11. Kang W, Reid KB. DMBT1, a regulator of mucosal homeostasis through the 
linking of mucosal defense and regeneration? FEBS Lett (2003) 540:21–5. 
doi:10.1016/S0014-5793(03)00217-5 
12. Ligtenberg AJ, Veerman EC, Nieuw Amerongen AV, Mollenhauer J. Salivary 
agglutinin/glycoprotein-340/DMBT1: a single molecule with variable compo-
sition and with different functions in infection, inflammation and cancer. Biol 
Chem (2007) 388:1275–89. doi:10.1515/BC.2007.158 
13. Madsen J, Mollenhauer J, Holmskov U. Review: gp-340/DMBT1 
in mucosal innate immunity. Innate Immun (2010) 16:160–7. 
doi:10.1177/1753425910368447 
14. Thornton DJ, Davies JR, Kirkham S, Gautrey A, Khan N, Richardson PS, et al. 
Identification of a nonmucin glycoprotein (gp-340) from a purified respiratory 
mucin preparation: evidence for an association involving the MUC5B mucin. 
Glycobiology (2001) 11:969–77. doi:10.1093/glycob/11.11.969 
15. Rundegren J, Arnold RR. Differentiation and interaction of secretory immu-
noglobulin A and a calcium-dependent parotid agglutinin for several bacterial 
strains. Infect Immun (1987) 55:288–92. 
16. Tino MJ, Wright JR. Glycoprotein-340 binds surfactant protein-A (SP-A) and 
stimulates alveolar macrophage migration in an SP-A-independent manner. 
Am J Respir Cell Mol Biol (1999) 20:759–68. doi:10.1165/ajrcmb.20.4.3439 
17. Thim L, Mortz E. Isolation and characterization of putative trefoil peptide 
receptors. Regul Pept (2000) 90:61–8. doi:10.1016/S0167-0115(00)00110-5 
18. Oho T, Bikker FJ, Nieuw Amerongen AV, Groenink J. A peptide domain of 
bovine milk lactoferrin inhibits the interaction between streptococcal surface 
protein antigen and a salivary agglutinin peptide domain. Infect Immun (2004) 
72:6181–4. doi:10.1128/IAI.72.10.6181-6184.2004 
19. Muller H, Renner M, Helmke BM, End C, Weiss C, Poeschl J, et al. Deleted in 
malignant brain tumors 1 is up-regulated in bacterial endocarditis and binds 
to components of vegetations. J Thorac Cardiovasc Surg (2009) 138:725–32. 
doi:10.1016/j.jtcvs.2009.05.021 
20. Mitoma M, Oho T, Shimazaki Y, Koga T. Inhibitory effect of bovine milk lactofer-
rin on the interaction between a streptococcal surface protein antigen and human 
salivary agglutinin. J Biol Chem (2001) 276:18060–5. doi:10.1074/jbc.M101459200 
21. End C, Bikker F, Renner M, Bergmann G, Lyer S, Blaich S, et al. DMBT1 func-
tions as pattern-recognition molecule for poly-sulfated and poly-phosphor-
ylated ligands. Eur J Immunol (2009) 39:833–42. doi:10.1002/eji.200838689 
22. Wickstrom C, Christersson C, Davies JR, Carlstedt I. Macromolecular 
organization of saliva: identification of ‘insoluble’ MUC5B assemblies and 
March 2016 | Volume 7 | Article 856
Reichhardt and Meri SALSA and Complement Activation
Frontiers in Immunology | www.frontiersin.org
non-mucin proteins in the gel phase. Biochem J (2000) 351(Pt 2):421–8. 
doi:10.1042/bj3510421 
23. Loimaranta V, Jakubovics NS, Hytonen J, Finne J, Jenkinson HF, Stromberg 
N. Fluid- or surface-phase human salivary scavenger protein gp340 exposes 
different bacterial recognition properties. Infect Immun (2005) 73:2245–52. 
doi:10.1128/IAI.73.4.2245-2252.2005 
24. Prakobphol A, Xu F, Hoang VM, Larsson T, Bergstrom J, Johansson I, et al. 
Salivary agglutinin, which binds Streptococcus mutans and Helicobacter pylori, 
is the lung scavenger receptor cysteine-rich protein gp-340. J Biol Chem (2000) 
275:39860–6. doi:10.1074/jbc.M006928200 
25. Madsen J, Tornoe I, Nielsen O, Lausen M, Krebs I, Mollenhauer J, et  al. 
CRP-ductin, the mouse homologue of gp-340/deleted in malignant brain 
tumors 1 (DMBT1), binds Gram-positive and Gram-negative bacteria and 
interacts with lung surfactant protein D. Eur J Immunol (2003) 33:2327–36. 
doi:10.1002/eji.200323972 
26. Haukioja A, Loimaranta V, Tenovuo J. Probiotic bacteria affect the compo-
sition of salivary pellicle and streptococcal adhesion in vitro. Oral Microbiol 
Immunol (2008) 23:336–43. doi:10.1111/j.1399-302X.2008.00435.x 
27. Rosenstiel P, Sina C, End C, Renner M, Lyer S, Till A, et al. Regulation of DMBT1 
via NOD2 and TLR4 in intestinal epithelial cells modulates bacterial recognition 
and invasion. J Immunol (2007) 178:8203–11. doi:10.4049/jimmunol.178.12.8203 
28. Jumblatt MM, Imbert Y, Young WW Jr, Foulks GN, Steele PS, Demuth DR. 
Glycoprotein 340 in normal human ocular surface tissues and tear film. Infect 
Immun (2006) 74:4058–63. doi:10.1128/IAI.01951-05 
29. Nagashunmugam T, Malamud D, Davis C, Abrams WR, Friedman HM. 
Human submandibular saliva inhibits human immunodeficiency virus type 
1 infection by displacing envelope glycoprotein gp120 from the virus. J Infect 
Dis (1998) 178:1635–41. doi:10.1086/314511 
30. Hartshorn KL, White MR, Mogues T, Ligtenberg T, Crouch E, Holmskov U. 
Lung and salivary scavenger receptor glycoprotein-340 contribute to the host 
defense against influenza A viruses. Am J Physiol Lung Cell Mol Physiol (2003) 
285:L1066–76. doi:10.1152/ajplung.00057.2003 
31. Holmskov U, Mollenhauer J, Madsen J, Vitved L, Gronlund J, Tornoe I, et al. 
Cloning of gp-340, a putative opsonin receptor for lung surfactant protein D. 
Proc Natl Acad Sci U S A (1999) 96:10794–9. doi:10.1073/pnas.96.19.10794 
32. Mollenhauer J, Herbertz S, Holmskov U, Tolnay M, Krebs I, Merlo A, et al. 
DMBT1 encodes a protein involved in the immune defense and in epithelial 
differentiation and is highly unstable in cancer. Cancer Res (2000) 60:1704–10. 
33. Mollenhauer J, Herbertz S, Helmke B, Kollender G, Krebs I, Madsen J, et al. 
Deleted in malignant brain tumors 1 is a versatile mucin-like molecule likely to 
play a differential role in digestive tract cancer. Cancer Res (2001) 61:8880–6. 
34. Kang W, Nielsen O, Fenger C, Madsen J, Hansen S, Tornoe I, et  al. The 
scavenger receptor, cysteine-rich domain-containing molecule gp-340 is dif-
ferentially regulated in epithelial cell lines by phorbol ester. Clin Exp Immunol 
(2002) 130:449–58. doi:10.1046/j.1365-2249.2002.01992.x 
35. Stoddard E, Cannon G, Ni H, Kariko K, Capodici J, Malamud D, et al. gp340 
expressed on human genital epithelia binds HIV-1 envelope protein and 
facilitates viral transmission. J Immunol (2007) 179:3126–32. doi:10.4049/
jimmunol.179.5.3126 
36. Schulz BL, Oxley D, Packer NH, Karlsson NG. Identification of two highly 
sialylated human tear-fluid DMBT1 isoforms: the major high-molecular-mass 
glycoproteins in human tears. Biochem J (2002) 366:511–20. doi:10.1042/
bj20011876 
37. Reichhardt MP, Jarva H, de Been M, Rodriguez JM, Jimenez Quintana 
E, Loimaranta V, et  al. The salivary scavenger and agglutinin in early life: 
diverse roles in amniotic fluid and in the infant intestine. J Immunol (2014) 
193:5240–8. doi:10.4049/jimmunol.1401631 
38. Sonesson M, Ericson D, Kinnby B, Wickstrom C. Glycoprotein 340 and sialic 
acid in minor-gland and whole saliva of children, adolescents, and adults. Eur 
J Oral Sci (2011) 119:435–40. doi:10.1111/j.1600-0722.2011.00879.x 
39. Ligtenberg AJ, Karlsson NG, Veerman EC. Deleted in malignant brain 
tumors-1 protein (DMBT1): a pattern recognition receptor with multiple 
binding sites. Int J Mol Sci (2010) 11:5212–33. doi:10.3390/ijms1112521 
40. Wu Z, Van Ryk D, Davis C, Abrams WR, Chaiken I, Magnani J, et  al. 
Salivary agglutinin inhibits HIV type 1 infectivity through interaction 
with viral glycoprotein 120. AIDS Res Hum Retroviruses (2003) 19:201–9. 
doi:10.1089/088922203763315704 
41. Jonasson A, Eriksson C, Jenkinson HF, Kallestal C, Johansson I, Stromberg N. 
Innate immunity glycoprotein gp-340 variants may modulate human suscepti-
bility to dental caries. BMC Infect Dis (2007) 7:57. doi:10.1186/1471-2334-7-57 
42. Mollenhauer J, Holmskov U, Wiemann S, Krebs I, Herbertz S, Madsen J, et al. 
The genomic structure of the DMBT1 gene: evidence for a region with sus-
ceptibility to genomic instability. Oncogene (1999) 18:6233–40. doi:10.1038/
sj.onc.1203071 
43. Mollenhauer J, Muller H, Kollender G, Lyer S, Diedrichs L, Helmke B, et al. 
The SRCR/SID region of DMBT1 defines a complex multi-allele system 
representing the major basis for its variability in cancer. Genes Chromosomes 
Cancer (2002) 35:242–55. doi:10.1002/gcc.10115 
44. Mollenhauer J, Helmke B, Muller H, Kollender G, Lyer S, Diedrichs L, et al. 
Sequential changes of the DMBT1 expression and location in normal lung 
tissue and lung carcinomas. Genes Chromosomes Cancer (2002) 35:164–9. 
doi:10.1002/gcc.10096 
45. Ligtenberg AJ, Veerman EC, Nieuw Amerongen AV. A role for Lewis a anti-
gens on salivary agglutinin in binding to Streptococcus mutans. Antonie Van 
Leeuwenhoek (2000) 77:21–30. doi:10.1023/A:1002054810170 
46. Eriksson C, Frangsmyr L, Danielsson Niemi L, Loimaranta V, Holmskov 
U, Bergman T, et al. Variant size- and glycoforms of the scavenger receptor 
cysteine-rich protein gp-340 with differential bacterial aggregation. Glycoconj 
J (2007) 24:131–42. doi:10.1007/s10719-006-9020-1 
47. Reid KB, Porter RR. Subunit composition and structure of subcomponent C1q 
of the first component of human complement. Biochem J (1976) 155:19–23. 
doi:10.1042/bj1550019 
48. Sellar GC, Blake DJ, Reid KB. Characterization and organization of the genes 
encoding the A-, B- and C-chains of human complement subcomponent C1q. 
The complete derived amino acid sequence of human C1q. Biochem J (1991) 
274(Pt 2):481–90. doi:10.1042/bj2740481 
49. Kojouharova MS, Tsacheva IG, Tchorbadjieva MI, Reid KB, Kishore U. 
Localization of ligand-binding sites on human C1q globular head region using 
recombinant globular head fragments and single-chain antibodies. Biochim 
Biophys Acta (2003) 1652:64–74. doi:10.1016/j.bbapap.2003.08.003 
50. Ligtenberg AJ, Bikker FJ, De Blieck-Hogervorst JM, Veerman EC, Nieuw 
Amerongen AV. Binding of salivary agglutinin to IgA. Biochem J (2004) 
383:159–64. doi:10.1042/BJ20040265 
51. White MR, Crouch E, Vesona J, Tacken PJ, Batenburg JJ, Leth-Larsen R, et al. 
Respiratory innate immune proteins differentially modulate the neutrophil 
respiratory burst response to influenza A virus. Am J Physiol Lung Cell Mol 
Physiol (2005) 289:L606–16. doi:10.1152/ajplung.00130.2005 
52. White MR, Crouch E, van Eijk M, Hartshorn M, Pemberton L, Tornoe I, et al. 
Cooperative anti-influenza activities of respiratory innate immune proteins 
and neuraminidase inhibitor. Am J Physiol Lung Cell Mol Physiol (2005) 
288:L831–40. doi:10.1152/ajplung.00365.2004 
53. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. Regulation of complement 
activation by C-reactive protein: targeting the complement inhibitory activity 
of factor H by an interaction with short consensus repeat domains 7 and 8-11. 
J Immunol (1999) 163:3957–62. 
54. Deban L, Jarva H, Lehtinen MJ, Bottazzi B, Bastone A, Doni A, et al. Binding 
of the long pentraxin PTX3 to factor H: interacting domains and function 
in the regulation of complement activation. J Immunol (2008) 181:8433–40. 
doi:10.4049/jimmunol.181.12.8433 
55. Fox S, Ryan KA, Berger AH, Petro K, Das S, Crowe SE, et al. The role of C1q 
in recognition of apoptotic epithelial cells and inflammatory cytokine pro-
duction by phagocytes during Helicobacter pylori infection. J Inflamm (Lond) 
(2015) 12:51. doi:10.1186/s12950-015-0098-8 
56. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory 
bowel disease: a cross-sectional study from central England. Eur J Gastroenterol 
Hepatol (2003) 15:1275–80. doi:10.1097/00042737-200312000-00004 
57. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, 
Nimmo ER, et al. Definition of phenotypic characteristics of childhood-on-
set inflammatory bowel disease. Gastroenterology (2008) 135:1114–22. 
doi:10.1053/j.gastro.2008.06.081 
58. Bak-Romaniszyn L, Szala A, Sokolowska A, Mierzwa G, Czerwionka-Szaflarska 
M, Swierzko AS, et al. Mannan-binding lectin deficiency in pediatric patients 
with inflammatory bowel disease. Scand J Gastroenterol (2011) 46:1275–8. do
i:10.3109/00365521.2011.594087 
March 2016 | Volume 7 | Article 857
Reichhardt and Meri SALSA and Complement Activation
Frontiers in Immunology | www.frontiersin.org
59. Aittoniemi J, Pertovaara M, Hulkkonen J, Pasternack A, Hurme M, Laippala 
P, et  al. The significance of mannan-binding lectin gene alleles in patients 
with primary Sjögren’s syndrome. Scand J Rheumatol (2002) 31:362–5. 
doi:10.1080/030097402320817095 
60. Slade JD, Luskin AT, Gewurz H, Kraft SC, Kirsner JB, Zeitz HJ. Inherited 
deficiency of second component of complement and HLA haplotype A10,B18 
associated with inflammatory bowel disease. Ann Intern Med (1978) 88:796–8. 
doi:10.7326/0003-4819-88-6-796 
61. Freeman HJ. Hereditary angioneurotic edema and familial Crohn’s disease. 
Can J Gastroenterol (2000) 14:337–9. 
62. Farkas H, Gyeney L, Nemesanszky E, Kaldi G, Kukan F, Masszi I, et  al. 
Coincidence of hereditary angioedema (HAE) with Crohn’s disease. Immunol 
Invest (1999) 28:43–53. doi:10.3109/08820139909022722 
63. Kolho KL, Paakkanen R, Lepistö AL, Wennerstom A, Meri S, Lokki ML. Novel 
associations between major histocompatibility complex and pediatric-onset 
inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2015). doi:10.1097/
MPG.0000000000000984 
64. Sandahl TD, Kelsen J, Dige A, Dahlerup JF, Agnholt J, Hvas CL, et  al. The 
lectin pathway of the complement system is downregulated in Crohn’s disease 
patients who respond to anti-TNF-alpha therapy. J Crohns Colitis (2014) 
8:521–8. doi:10.1016/j.crohns.2013.11.007 
65. Diegelmann J, Czamara D, Le Bras E, Zimmermann E, Olszak T, Bedynek A, 
et al. Intestinal DMBT1 expression is modulated by Crohn’s disease-associated 
IL23R variants and by a DMBT1 variant which influences binding of the tran-
scription factors CREB1 and ATF-2. PLoS One (2013) 8:e77773. doi:10.1371/
journal.pone.0077773 
66. Kim TH, Lee SH, Lee HM, Jung HH, Lee SH, Cho WS, et al. Increased expres-
sion of glycoprotein 340 in the ethmoid sinus mucosa of patients with chronic 
sinusitis. Arch Otolaryngol Head Neck Surg (2007) 133:1111–4. doi:10.1001/
archotol.133.11.1111 
67. Renner M, Bergmann G, Krebs I, End C, Lyer S, Hilberg F, et  al. DMBT1 
confers mucosal protection in  vivo and a deletion variant is associated 
with Crohn’s disease. Gastroenterology (2007) 133:1499–509. doi:10.1053/j.
gastro.2007.08.007 
68. Hamm CM, Reimers MA, McCullough CK, Gorbe EB, Lu J, Gu CC, et  al. 
NOD2 status and human ileal gene expression. Inflamm Bowel Dis (2010) 
16:1649–57. doi:10.1002/ibd.21208 
69. Muller H, End C, Weiss C, Renner M, Bhandiwad A, Helmke BM, et  al. 
Respiratory deleted in malignant brain tumours 1 (DMBT1) levels increase 
during lung maturation and infection. Clin Exp Immunol (2008) 151:123–9. 
doi:10.1111/j.1365-2249.2007.03528.x 
70. Madsen J, Sorensen GL, Nielsen O, Tornoe I, Thim L, Fenger C, et al. A vari-
ant form of the human deleted in malignant brain tumor 1 (DMBT1) gene 
shows increased expression in inflammatory bowel diseases and interacts 
with dimeric trefoil factor 3 (TFF3). PLoS One (2013) 8:e64441. doi:10.1371/
journal.pone.0064441 
71. Aamann L, Vestergaard EM, Gronbaek H. Trefoil factors in inflammatory 
bowel disease. World J Gastroenterol (2014) 20:3223–30. doi:10.3748/wjg.v20.
i12.3223 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Reichhardt and Meri. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
